Photo: Qiagen

Qiagen: Thierry Bernard remains CEO

In October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.

Now, the provisional arrangement has come to an end: in March, Thierry Bernard was appointed CEO of Qiagen NV. The next Annual General Meeting in June 2020 is expected to confirm him as CEO and Managing Director, as well as CFO and Managing Director Roland Sackers, with whom Bernard has worked closely in recent months. Bernard has been with Qiagen since 2015, prior to his appointment as interim CEO, as Senior Vice President, Head of Molecular Diagnostics Business Area.

Håkan Björklund, Chairman of Qiagen's Supervisory Board, said: “He is a strong and proven leader with extensive industry expertise and deep customer relationships. Most important, he has shown the energy and skill to drive QIAGEN forward and has been a key leader in achieving the agreement for QIAGEN to be acquired by Thermo Fisher Scientific in a transaction that remains on track for completion in the first half of 2021 and will create a bright future for our trusted QIAGEN brand, employees and product portfolio.”

QIAGEN announced that it has received emergency use authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.